Detalles de la búsqueda
1.
Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
Breast Cancer Res
; 18(1): 70, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27368372
2.
Erratum to: Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer.
Breast Cancer Res
; 19(1): 17, 2017 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28183333
3.
Discovery of Orally Bioavailable Ligand Efficient Quinazolindiones as Potent and Selective Tankyrases Inhibitors.
ACS Med Chem Lett
; 12(6): 1005-1010, 2021 Jun 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34141085
4.
Discovery and Pharmacological Characterization of JNJ-64619178, a Novel Small-Molecule Inhibitor of PRMT5 with Potent Antitumor Activity.
Mol Cancer Ther
; 20(12): 2317-2328, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583982
5.
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis.
Mol Cancer Ther
; 19(10): 2044-2056, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32747419
6.
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Cancer Immunol Res
; 7(9): 1457-1471, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31331945
7.
Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.
ACS Med Chem Lett
; 9(7): 623-628, 2018 Jul 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30034590
8.
Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.
Mol Cancer Ther
; 16(11): 2572-2585, 2017 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28830985
9.
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells.
MAbs
; 9(1): 114-126, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27786612
10.
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor.
Mol Cancer Ther
; 16(6): 1010-1020, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28341788
11.
Identification and characterization of potent small molecule inhibitor of hemorrhagic fever New World arenaviruses.
Antiviral Res
; 69(2): 86-97, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16343651
12.
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.
Cancer Res
; 76(13): 3942-53, 2016 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27216193
13.
Tumor-specific intravenous gene delivery using oncolytic adenoviruses.
Cancer Gene Ther
; 12(1): 19-25, 2005 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-15514685
14.
Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol.
Antiviral Res
; 68(1): 18-26, 2005 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-16112208
15.
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
PLoS One
; 8(7): e67583, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23844038
16.
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.
ACS Med Chem Lett
; 4(3): 358-62, 2013 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900673
17.
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.
Mol Cancer Ther
; 11(3): 720-9, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22169769
18.
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Mol Cancer Ther
; 11(4): 909-20, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22389471
19.
Pooled shRNA screen for sensitizers to inhibition of the mitotic regulator polo-like kinase (PLK1).
Oncotarget
; 2(12): 1254-64, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-22248814
20.
GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition.
Clin Cancer Res
; 17(5): 989-1000, 2011 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21245089